anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

200,641-200,700 of 319,975

filter-aware
01
Slide 1
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Attention1 hit
02
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations 1 hit
03
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations 1 hit
04
The slide presents a 3x2 grid of bar charts comparing revenue and EBITDA for Total Advantage, Sales Segment, and Marketing Segment.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · OverviewLoop · So What Cascade1 hit
05
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · OverviewLoop · So What Cascade1 hit
06
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Key TakeawaysLoop · Cost Of Inaction1 hit
07
Includes a waterfall-style chart showing debt components and a detailed table for debt and equity.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Capitalization Summary1 hit
08
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
09
Includes footnotes references (1) through (9) which are not explicitly rendered on this slide.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
10
The slide presents two separate tables for Sales and Marketing segments, detailing various add-backs and adjustments to arrive at Adjusted EBITDA.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
11
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
12
This is the fourth page of a four-part appendix disclosure regarding non-GAAP financial measures.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
13
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations 1 hit
01
Slide 1
Includes company logo, tagline, date, and ticker symbol.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a split-screen layout with a photo on the left and text on a dark blue background on the right.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle1 hit
04
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The slide uses a Gantt-style chart to represent clinical trial progress for three distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle1 hit
06
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
09
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a pie chart for segmentation and a timeline/number line for diagnostic age, followed by key clinical metrics.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · AgitateLoop · Mece Breakdown1 hit
11
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · SolutionLoop · Mece Breakdown1 hit
12
The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to demonstrate drug efficacy.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
17
Includes a timeline-based progression of symptoms from infancy to adulthood.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
18
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
19
Includes statistical significance markers and clinical guideline thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
20
Includes statistical significance (p-values) and MCID reference lines for GMFM-E.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
21
The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
22
Data presented as n (%).Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
23
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
25
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
26
Includes footnotes detailing cash equivalents and share breakdown.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
27
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
28
The slide uses a process flow diagram to contrast intracellular metabolism with plasma-based enzymatic intervention.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
Includes histological images of liver tissue and a dot plot showing BMD improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
Clinical trial baseline data table.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
32
The table displays mean/SD and median/range for continuous variables, and counts/percentages for categorical variables.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
33
The slide uses a box plot to visualize longitudinal clinical trial data.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
34
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
35
Includes a study design timeline and clinical endpoint data tables/charts.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
36
The slide uses standard clinical metrics for motor function assessment.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
37
The slide uses a process flow diagram to illustrate the clinical trial structure.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
38
The table highlights specific clinical improvements for six individual patients, emphasizing normalization of mobility.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
39
The slide uses a split-screen layout: left side is market sizing/segmentation, right side is a 2x2 strategic framework for launch execution.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Attention1 hit
02
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
03
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
04
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
05
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Interest1 hit
06
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
07
The slide uses a linear process flow to demonstrate the progression of a customer engagement.Aeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit
08
Uses a 2x2-style quadrant map to illustrate competitive advantage.Aeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit